Lucid Diagnostics (LUCD) Net Income towards Common Stockholders (2020 - 2026)
Lucid Diagnostics posted quarterly Net Income towards Common Stockholders of -$23.6 million for Q1 2026, up 34.4% year-on-year from -$17.6 million in Q1 2025, and down 45.26% on a QoQ basis from -$16.3 million in Q4 2025.
Lucid Diagnostics (LUCD) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$23.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 34.4% year-over-year to -$23.6 million; the trailing twelve-month figure through Mar 2026 stood at -$58.2 million (up 17.98% YoY), and the FY2025 full-year result was -$70.6 million, down 33.09% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$23.6 million, down from -$16.3 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$7.9 million in Q2 2025 and bottomed at -$36.0 million in Q1 2025.
- The 5-year median for Net Income towards Common Stockholders is -$14.2 million (2023), against an average of -$15.1 million.
- The widest annual swing landed in 2022, when Net Income towards Common Stockholders plunged 235.89%; it then jumped 34.4% in 2026.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$14.9 million in 2022, then gained by 27.45% to -$10.8 million in 2023, then slipped by 6.57% to -$11.5 million in 2024, then tumbled by 40.94% to -$16.3 million in 2025, then plunged by 45.26% to -$23.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$23.6 million (Q1 2026), -$16.3 million (Q4 2025), and -$10.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Lucid Diagnostics | 145.00 Mn | 117.12 Mn | -325,000.00 | -23.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.63 Mn |
| Dec 31, 2025 | -16.27 Mn |
| Sep 30, 2025 | -10.40 Mn |
| Jun 30, 2025 | -7.89 Mn |
| Mar 31, 2025 | -36.02 Mn |
| Dec 31, 2024 | -11.54 Mn |
| Sep 30, 2024 | -12.37 Mn |
| Jun 30, 2024 | -11.01 Mn |
| Mar 31, 2024 | -18.11 Mn |
| Dec 31, 2023 | -10.83 Mn |
| Sep 30, 2023 | -14.21 Mn |
| Jun 30, 2023 | -11.38 Mn |
| Mar 31, 2023 | -16.25 Mn |
| Dec 31, 2022 | -14.93 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -14.62 Mn |
| Mar 31, 2022 | -12.27 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -6.96 Mn |
| Jun 30, 2021 | -6.16 Mn |
| Mar 31, 2021 | -3.65 Mn |
| Dec 31, 2020 | -2.73 Mn |
| Sep 30, 2020 | -2.02 Mn |